BSR_08_0188_C3_S52
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.400
- ANGIOGENESIS+0.280
- HEDGEHOG_SIGNALING+0.280
- WNT_BETA_CATENIN_SIGNALING+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
- APICAL_JUNCTION+0.210
- MYOGENESIS+0.210
- BILE_ACID_METABOLISM+0.190
- NOTCH_SIGNALING+0.190
- ESTROGEN_RESPONSE_EARLY+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.460
- E2F_TARGETS-0.450
- G2M_CHECKPOINT-0.440
- ALLOGRAFT_REJECTION-0.350
- INFLAMMATORY_RESPONSE-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- MTORC1_SIGNALING-0.290
- MYC_TARGETS_V2-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 87fad31a-da7d-4904-93bd-29a7290a316b | — | — | 0.876 |
| 2 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.862 |
| 3 | BSR_18_0092_S48 | — | A | 0.859 |
| 4 | MBCProject_0504_T1_RNA | — | A | 0.856 |
| 5 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.848 |
| 6 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.844 |
| 7 | 20030017.LumA | — | B | 0.840 |
| 8 | C3L-02165 | — | cohortA2 | 0.832 |
| 9 | SRR1313111 | — | A | 0.828 |
| 10 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |